• Home
• Reports
• Companies

• Partnering Search
• Profiling
• Deal Negotiation

• Out-licensing
• In-licensing
• Services

• PL Intelligence
• Deals review
• Industry news

• Press releases
• Events
• Newsletter

Decision Resources Inc.

Pharmacor

Disease Market Intelligence reports: business assessment of marketed drugs and drugs in development, current and emerging therapies, the medical practice, the unmet need and the market potential of emerging drugs.

Ultimate output is a bottom-up epidemiology-driven sales forecast on a country level (G7: US, UK, F, D, I, E, and Japan) and the generic molecule level 2007-2012-2017, based on both primary and extensive secondary market research.

Key Features:

• Bottom-up, epidemiology-driven sales forecast for the next decade (2007-2012-2017)
• Etiology & Pathophysiology
• Epidemiology
• Current Therapies
• Medical Practice
• Unmet Need
• Emerging Therapies
• Market Outlook with Excel-based Interactive Forecast Tool (IFT) for the seven Major Markets

Key Benefits: 

• Better positioning your drug therapy in a given therapeutic area
• New product planning and assessing the commercial potential of new therapies
• Identifying emerging competitors and their impact in a disease area
• Understanding the market potential for your drug therapy within a disease indication in major markets worldwide
• Understanding the clinicians perspective on treating patients in a given disease area

Format: +/- 250 page report: Interactive html, pdf-file, PowerPoint slide-deck, Interactive Forecast Tool (IFT) in Excel, Market Assumptions file in Excel. Hard copies on request.

Contact:

DecisionBase

Optimizing your Investments in Drug Development using in-depth analysis of unmet need, physician expectation, reimbursement and commercial dynamics. The Drug Comparator Model is an interactive display which compares the key attributes of therapies and identifies the future clinical "gold standard". Each report includes two physician-defined Profiles that highlight physicians' expectations of emerging therapies in terms of how much better or worse the therapy performs relative to a comparator drug. The profiles are tested with physicians to determine market potential based on price and patient share.

Key Features: 

• Regulatory and Labelling Status, Pricing and Reimbursement
• Promotional Activity
• Prescriber-Defined Opportunity and Unmet Need
• Target Product Profile
• Prescriber Weighting of Clinical End Points
• Thought-Leader-Derived Scoring of Drugs
• Drug Comparator Model
• Current Drugs' Impact on Quality of Life
• Disease Severity in the Untreated Patient
• Patient Population, Current Treatments
• Market Forecast, Emerging Product Profiles

Key Benefits:

• Identifying key drug development opportunities in a disease indication
• Evaluating physician receptivity to different product attributes
• Gauge where physicians are dissatisfied with current therapies.
• Developing demand-based forecasts for your products
• Evaluating the commercial attractiveness/opportunity of drug therapies under development
• Identifying the strengths and weaknesses of current and emerging therapies versus gold standard
• Developing target product profile for your product
• Product portfolio planning
• Determine which clinical end points have the greatest impact on prescribing behaviour.
• Identify and size disease opportunities in a disease.
• Identify the challenges and opportunities associated with entering a disease market.
• Decide if your target drug has the attributes needed for success.
• Compare your product to competitors today and to drugs in development.
• Value an in-license opportunity or in-house development

Format: interactive database through on line delivery &derived from that a +/- 100 page report in PDF.

Contact:

PatientBase

PatientBase

PatientBase is the premier epidemiology database, providing complete coverage of more than 140 disease indications including over 711 patient populations across the G7 pharmaceutical markets (U.S., France, Germany, Italy, Spain, United Kingdom, Japan). 

PatientBase's rich data set and easy-to-use Web interface allow you to focus on the age cohort, country, disease subtype (including comorbidity), disease subpopulation segment of interest or specific years to meet your unique needs and research objectives. And you can easily manipulate the database to create custom epidemiological projections of key patient segments.

The methodologies and sources behind the data are fully transparent.  For each indication covered in PatientBase, Decision Resources' team of epidemiologists provide the following:

• Full discussions of the reasons for including studies as sources of the data underlying our patient population estimates and projections, and reasons for not choosing other studies;
• A full bibliography of all sources considered and discussed, even those not chosen as the basis of the patient population estimates. In addition to published sources, we also conduct our own analyses of many government databases to obtain prevalence and incidence estimates;
• Detailed discussion of the methodology used to derive estimates for each major-market nation; and
• A source table for easy reference to key sources and definitions used for each country.

What can you do with PatientBase?

PatientBase allows you to:

• Make decisions based on the most up-to-date epi data
• View your data query in a variety of display formats
• Export your findings into Excel or your own company’s interactive forecasting tool
• View a year-by-year epidemiological forecast over ten years with the ability to customize the forecast period or interval
• Identify disease growth trends
• Quickly find data using a comprehensive search function

PatientBase now offers treatable pools for its cancer indications.

Treatable pools can be used for greater accuracy in forecasting and sizing a cancer
market by taking into account both relevant patient populations AND patient populations by stages. To calculate the drug-treatable pool, we make assumptions relating to rate of progression from early to late stages using data relating to survival and treatment outcome, and use these factors to model the number of incident patients who progress from early to more advanced stages of disease to capture disease recurrence and better reflect the number of patients available for treatment (drug-treatable pool).

All assumptions are fully documented, with relevant studies cited and rationales for selection provided.

Contact:

Treatment Algorithm Insight Series

Combines primary research with 150 physicians with longitudinal patient-level claims data to quantify share by lines of therapy and provide insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

Key Features:

• Summary of US. medical practice based on interviews with leading experts in the field.
• Qualitative diagnosis/referral/treatment algorithm for the US.
• Drug usage by lines of therapy (1st, 2nd, 3rd line).
• Discussion of key freeform combinations by lines of therapy.
• Product share (class and specific compound level) within each line of therapy (1st, 2nd, 3rd line).
• Progression of therapy from key 1st line products
• Pathway to key therapies from previous therapies
• Qualitative analysis of 2-year forecast incorporating upcoming launches, changes in reimbursement, etc

 Key Benefits:

• Understand current treatment patterns and anticipate future market dynamics.
• Drive product growth through accurate knowledge of your product's positioning among the linesof therapy and why physicians use it at that point.
• Target specific competitorsthat are preceding or following your productand benefit fromactionable analysis ofthe path to treatment and physicians' decision parameters.
• Develop more sophisticated market-forecasting patient-flow models based on the unique, accurate informationwe provide regardingthe percentage of patients receiving your product at specific stages in the line of therapy.

 Format: 100 - 120 page report: PDF-files.

Contact:

EMERGING MARKETS REPORTS (China, India, Brazil, Russia)

Each report assesses the commercial opportunity in one of the emerging pharmaceutical markets for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices. Analysis of the market dynamics in key urban areas are presented separately.

Key Features:

• Sizing and projections for the diagnosed & treated patient populations at national and city-specific levels.
• Projections for future patient populations with access to Western medicine based on trends in lifestyle, urbanization & economic status.
• Current treatment patterns and drivers of choice from physicians in key urban areas.
• Physician-defined unmet needs in diagnosing and treating the disease.
• Disease-specific pricing & reimbursement environment.
• Key drivers of market growth and analysis of dynamics for the individual major city markets.
• 5-year market forecast at the drug level, broken out by urban & rural areas and by sales from multinational and local companies.

Key Benefits:

• Assess your commercial opportunity for Western medicine in the key emerging pharmaceutical markets.
• Understand the physician treatment patterns & drivers of choice in key 1^st & 2nd tier cities based on primary research
• Formulated an informed view of challenges and opportunities for new entrants to the emerging pharmaceutical markets.
• Gain a clear perspective of the 5-year market forecast at the drug level, broken out by urban and rural areas, and by sales from multinational and local companies when relevant.

Format: 200 page report: Interactive html, forecast Excel, PowerPoint slide-deck, PDF-file.

Contact:

Primary contact

Press releases

Patient-targeted messaging for Emerging Multiple Sclerosis agents needs to highlight efficacy and preservation of quality of life (30 Oct 2009)
Surveyed neurologists perceive the efficacy of Merck Serono’s Rebif nearly as equivalent to that of Biogen Idec’s Tysabri, according to a new report from Decision Resources

Continued uptake of Tnf-Alpha Inhibitors and Interleukin Inhibitors will drive US $2.2 billion growth in the Psoriasis drug market (26 Oct 2009)
Abbott/Eisai’s Humira will achieve blockbuster sales and become the market leader in 2018, according to a new report from Decision Resources

Tnf-Alpha Inhibitors will continue to dominate first- and second-line Biologic Therapy for the treatment of Rheumatoid Arthritis through 2011 (22 Oct 2009)
However, Tnf-Alpha Inhibitors are not immune to competition from Roche’s emerging Il-6 Inhibitor Actemra, according to a new report from Decision Resources

Patient-Flow models will need to take into account that over ten percent of patients sta

Majority of surveyed physicians prescribe Cymbalta and Lyrica for treatment of Fibromyalgia but neither agent has the majority of its uses in first line (21 Oct 2009)
Cymbalta is the agent most likely to lose patient share to Savella over the next two years, according to a new report from Decision Resources

Patient-flow models will need to take into account that the highest percentage of patients take Lyrica

Sales of Glaxosmithkline’s Relenza likely to increase during the A/H1N1 2009 pandemic as Tamiflu-Resistant Strains of the virus spread (15 Oct 2009)
The nature of pandemics makes cell-based Vaccines an ideal choice over Egg-Based Vaccines

New special report on Swine Flu now available from Decision Resources

Profile